Kesimpta vs Tysabri
Side-by-side cost comparison based on Medicare Part D data
Kesimpta
Ofatumumab
Manufactured by Novartis
Tysabri
Natalizumab
Manufactured by Biogen
Kesimpta costs 15% less per claim than Tysabri ($8,425.00 vs $9,952.00). A generic version of Kesimpta is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Kesimpta | Tysabri |
|---|---|---|
| Avg Cost Per Claim | $8,425.00 | $9,952.00 |
| Total Medicare Spending | $1.6B | $1.2B |
| Total Beneficiaries | 22,000 | 11,000 |
| Total Claims | 186,000 | 124,000 |
| Annual Cost/Patient | $71,227.00 | $112,182.00 |
| Year-over-Year Change | +68.4% | -3.2% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Novartis | Biogen |
| Condition | Multiple Sclerosis | Multiple Sclerosis |
| Generic Name | Ofatumumab | Natalizumab |
Kesimpta vs Tysabri: What the Data Shows
Kesimpta (Ofatumumab) and Tysabri (Natalizumab) are both used to treat multiple sclerosis. Based on Medicare Part D data, Kesimpta costs $8,425.00 per claim, which is 15% less than Tysabri at $9,952.00 per claim.
Medicare spent $1.6B on Kesimpta and $1.2B on Tysabri. In terms of patient reach, Kesimpta serves more beneficiaries (22,000 vs 11,000).
Year-over-year spending changed +68.4% for Kesimpta and -3.2% for Tysabri. Kesimpta saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Kesimpta is cheaper at $8,425.00 per claim, compared to $9,952.00 for Tysabri. That makes Kesimpta about 15% less expensive per claim based on Medicare Part D data.
Yes, both Kesimpta and Tysabri are used to treat multiple sclerosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Ofatumumab and generic Natalizumab can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $1.6B on Kesimpta covering 22,000 beneficiaries, and $1.2B on Tysabri covering 11,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.